Abstract:High-risk human papillomavirus (HPV)16/18 infection in the development of lung cancer has previously been identified, and fragile histidine triad (FHIT) loss and p53 mutation are frequently observed in the disease. However, the association between these factors has not been well studied. The present study aimed to further investigate the significance of HPV infection, FHIT loss and p53 mutations in the development of lung cancer and their possible associations. DNA was extracted from paraffin-embedded specimens from 88 cases of squamous cell carcinoma (SCC), 56 of adenocarcinoma (AC), 36 of small cell lung carcinoma (SCLC) and 110 non-cancer control cases of lung neoplasms. The prevalence of HPV infection was determined by polymerase chain reaction analysis, and FHIT loss and p53 mutations were detected by immunohistochemistry. The (2), Fisher's exact and Pearson correlation tests were applied for statistical analysis. The results of the present study demonstrated that HPVL1 (the major capsid protein of HPV), HPV16 and HPV18 infection were more prevalent in the lung cancer samples compared with the non-cancer controls (all P<0.001). FHIT loss occurred more frequently in the lung cancer samples (44.44%) compared with the non-cancer controls (7.25%) (P<0.001). FHIT loss in the HPVL1-positive group was significantly increased compared with the HPVL1-negative group in the lung cancer cases and the non-cancer controls (P<0.05). In the lung cancer cases, the p53 mutation rates in the HPVL1- and HPV16/18-positive groups were significantly increased compared with the HPVL1- and HPV16/18-negative groups (P<0.05). In the 180 lung cancer cases, the coexistence rate of FHIT loss and a history of smoking was 38.33% (69/180; Pearson contingency coefficient of r=0.318; P<0.001). FHIT loss and p53 mutation exhibited a synergistic effect on HPV-associated lung cancer (Pearson contingency coefficient r=0.357, P<0.001). The present study demonstrated that FHIT loss may be important in the occurrence of lung cancer, particularly in lung SCCs. FHIT loss may therefore be used as an early indicator for lung cancer, particularly for patients with a history of smoking. HPV infection in lung tumorigenesis may, at least in part, be mediated through FHIT loss. FHIT loss and p53 mutation may coordinate together in the development of HPV-associated lung cancer, and accelerate the occurrence and development of lung cancer.

Quantitative Assessment Of The Diagnostic Role Of Fhit Promoter Methylation In Non-Small Cell Lung Cancer

Regulation of Dna Methylation on the Expression of the Fhit Gene Contributes to Cervical Carcinoma Cell Tumorigenesis

Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer

The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review

The Aberrant Methylation of Fragile Histidine Triad (FHIT) Gene and Its Significance of the Expression of FHIT Protein in Lung Cancer

A study on the allelic deletion and mutation of FHIT gene in human non-small cell lung cancer

A study on transcript abnormalities of FHIT gene in human non-small cell lung cancer

The Clinicopathological Significance and Drug Target Potential of FHIT in Breast Cancer, a Meta-Analysis and Literature Review.

Study of mRNA Expressions of FHIT Genes in Patients with Non- small Cell Lung Cancer

Determination of FHIT and CDKN2A Promoter Methylation Levels in Hazak's Esophageal Cancer Tissue Based on Methylation-sensitive High Resolution Melting Analysis and Its Clinical Significance

Quantitative Assessment of Gene Promoter Methylation in Non-Small Cell Lung Cancer Using Methylation-Sensitive High-Resolution Melting.

The significance of FHIT gene detection for the diagnosis of lung cancer in transbronchial biopsy tissue samples and sputum samples

Reduction of FHIT Gene Expression in Primary Lung Cancer

Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.

Methylation of Antioncogen at 3p in Non-Small Cell Lung Cancer

Quantitative Assessment of the Diagnostic Role of APC Promoter Methylation in Non-Small Cell Lung Cancer.

Aberrant Methylation of CDH13 Can Be a Diagnostic Biomarker for Lung Adenocarcinoma

SCT Promoter Methylation is a Highly Discriminative Biomarker for Lung and Many Other Cancers

Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer

Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development

Methylation Status of HLTF Gene Promoter in the Tissues and Plasma of Gastric Cardiac Adenocarcinoma and Precancerous Lesions: a Comparative Study